SG10202106345VA - Macrocyclic mcl-1 inhibitors and methods of use - Google Patents

Macrocyclic mcl-1 inhibitors and methods of use

Info

Publication number
SG10202106345VA
SG10202106345VA SG10202106345VA SG10202106345VA SG10202106345VA SG 10202106345V A SG10202106345V A SG 10202106345VA SG 10202106345V A SG10202106345V A SG 10202106345VA SG 10202106345V A SG10202106345V A SG 10202106345VA SG 10202106345V A SG10202106345V A SG 10202106345VA
Authority
SG
Singapore
Prior art keywords
inhibitors
methods
mcl
macrocyclic
macrocyclic mcl
Prior art date
Application number
SG10202106345VA
Other languages
English (en)
Inventor
Wilfried Braje
George Doherty
Katja Jantos
Cheng Ji
Andrew Judd
Aaron Kunzer
Anthony Mastracchio
Xiaohong Song
Andrew Souers
Gerard Sullivan
Zhi-Fu Tao
Jesse Teske
Xilu Wang
Michael Wendt
Thomas Penning
Chunqiu Lai
Andreas Kling
Frauke Pohlki
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of SG10202106345VA publication Critical patent/SG10202106345VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG10202106345VA 2017-08-15 2018-08-15 Macrocyclic mcl-1 inhibitors and methods of use SG10202106345VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
SG10202106345VA true SG10202106345VA (en) 2021-07-29

Family

ID=65362347

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202001182QA SG11202001182QA (en) 2017-08-15 2018-08-15 Macrocyclic mcl-1 inhibitors and methods of use
SG10202106345VA SG10202106345VA (en) 2017-08-15 2018-08-15 Macrocyclic mcl-1 inhibitors and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202001182QA SG11202001182QA (en) 2017-08-15 2018-08-15 Macrocyclic mcl-1 inhibitors and methods of use

Country Status (21)

Country Link
US (3) US10676485B2 (pt)
EP (2) EP3652184A1 (pt)
JP (1) JP2020531433A (pt)
KR (1) KR20200041942A (pt)
CN (1) CN111818917A (pt)
AU (1) AU2018316620A1 (pt)
BR (1) BR112020003180A2 (pt)
CA (1) CA3073112A1 (pt)
CL (2) CL2020000363A1 (pt)
CO (1) CO2020002678A2 (pt)
CR (1) CR20200124A (pt)
EC (1) ECSP20018703A (pt)
IL (1) IL272681A (pt)
MX (1) MX2020001717A (pt)
PH (1) PH12020500327A1 (pt)
RU (1) RU2020110517A (pt)
SG (2) SG11202001182QA (pt)
TW (1) TW201920194A (pt)
UA (1) UA126586C2 (pt)
UY (1) UY37843A (pt)
WO (1) WO2019035911A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668503A4 (en) * 2017-08-15 2021-04-07 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
AU2018316620A1 (en) * 2017-08-15 2020-03-12 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｅｌ-１抑制劑以及使用方法
BR112020003254A2 (pt) 2017-08-15 2020-10-27 Agios Pharmaceuticals, Inc. moduladores da piruvato quinase e uso destes
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
JP2020533317A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 特異的ａｋｔ３活性化剤およびその使用
CA3136088A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3202759A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2276346T3 (en) 2008-04-30 2017-02-27 Nat Health Research Institutes FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
SG11201903326RA (en) 2016-10-28 2019-05-30 Servier Lab Liposomal formulation for use in the treatment of cancer
EP3567043B1 (en) 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AU2018316620A1 (en) * 2017-08-15 2020-03-12 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環ｍｅｌ-１抑制劑以及使用方法
EP3668503A4 (en) * 2017-08-15 2021-04-07 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Also Published As

Publication number Publication date
US10676485B2 (en) 2020-06-09
AU2018316620A1 (en) 2020-03-12
UA126586C2 (uk) 2022-11-02
BR112020003180A2 (pt) 2020-09-15
IL272681A (en) 2020-03-31
KR20200041942A (ko) 2020-04-22
TW201920194A (zh) 2019-06-01
EP3988555A1 (en) 2022-04-27
RU2020110517A3 (pt) 2022-03-23
UY37843A (es) 2019-03-29
JP2020531433A (ja) 2020-11-05
CO2020002678A2 (es) 2020-08-10
MX2020001717A (es) 2020-10-08
CR20200124A (es) 2020-09-28
SG11202001182QA (en) 2020-03-30
CN111818917A (zh) 2020-10-23
PH12020500327A1 (en) 2020-10-12
ECSP20018703A (es) 2020-04-22
EP3652184A4 (en) 2020-05-20
US20200325153A1 (en) 2020-10-15
US20190144465A1 (en) 2019-05-16
US20230183261A1 (en) 2023-06-15
CA3073112A1 (en) 2019-02-21
CL2020000363A1 (es) 2020-06-12
RU2020110517A (ru) 2021-09-16
WO2019035911A1 (en) 2019-02-21
EP3652184A1 (en) 2020-05-20
CL2020002943A1 (es) 2021-03-12

Similar Documents

Publication Publication Date Title
IL272681A (en) MCL-1 macrocyclic inhibitors and methods of use
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
EP3668503A4 (en) MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
EP3700527A4 (en) PAPD5 INHIBITORS AND THEIR METHODS OF USE
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
HK1258821A1 (zh) Menin-mll的橋接雙環抑制劑及其使用方法
HK1248499A1 (zh) 可擴張體裝置和使用方法
EP3684361A4 (en) MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
IL267291B (en) Actonucleotidase inhibitors and methods of using them
EP3668502A4 (en) MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
ZA201905677B (en) Glycan-interacting compounds and methods of use
EP3510040A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
EP3268369A4 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
IL259801A (en) ezh2 inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
SI3700902T1 (sl) Inhibitorji trpc6
IL274504A (en) 2ACSS inhibitors and methods of their use
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
IL267238A (en) The paranase inhibitors and their use
IL283782A (en) Analosomes and methods of use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
PL3362450T3 (pl) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
IL267243A (en) The paranase inhibitors and their use
EP3576745A4 (en) NGLY1 INHIBITORS AND THEIR METHODS OF USE
GB201709186D0 (en) Construction block and methods of use